The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy (Q36548740)

14 August 2017

1 reference

title

The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy (English)

1 reference

14 August 2017

1 reference

David Warr

1

1 reference

PubMed ID

16872268

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

12

1 reference

14 August 2017

1653-1658

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

14 August 2017

1 reference

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Aprepitant--a novel NK1-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Quality of life consequences of chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Modulation of cytochrome P450 activity: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1653

10.1517/14656566.7.12.1653

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16872268